Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma By Ogkologos - October 5, 2026 50 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement MOST POPULAR Study of More than Half a Million Women Links Regular Mammograms... March 10, 2021 Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... September 7, 2022 Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... September 24, 2020 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Load more HOT NEWS Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... Could proton beam therapy improve throat cancer treatment?
